Brief: Astrazeneca Pharma India Receives Permission For Voluntary Withdrawal Of Indication Of Olaparib (Lynparza)
21/05/2024 15:34
May 21 (Reuters) - Astrazeneca Pharma India Ltd
ASTR.NS :
* ASTRAZENECA PHARMA INDIA LTD - RECEIVED PERMISSION FOR
VOLUNTARY
WITHDRAWAL OF INDICATION OF OLAPARIB (LYNPARZA)
* ASTRAZENECA PHARMA INDIA LTD - INDICATION FOR TREATMENT OF
PATIENT WITH GBRCA MUTATION AND ADVANCED OVARIAN CANCER
Source text for Eikon: ID:nBSE6MWs23
Further company coverage: ASTR.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan
India's Astrazeneca Pharma logs worst slide in two months on quarterly profit drop
Brief: Astrazeneca Pharma India March-Quarter PAT 448.8 Million Rupees
Brief: Astrazeneca Pharma India Recommends Dividend Of 36 Rupees Per Equity Share For Fy2025-26
Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab (Imfinzi) For Additional Indication